Logotype for Lytix Biopharma

Lytix Biopharma (LYTIX) investor relations material

Lytix Biopharma Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Lytix Biopharma
Q2 2025 earnings summary28 Aug, 2025

Executive summary

  • Advancing toward commercialization with a robust clinical pipeline, including Ruxotemitide (LTX-315) moving toward Phase III in basal cell carcinoma and ongoing Phase II in melanoma, supported by a partnership with Verrica Pharmaceuticals.

  • Completed patient treatment in late-stage melanoma trial (ATLAS-IT-05), showing 40% disease control in a challenging population.

  • Significant reduction in Q2 2025 net loss, driven by a NOK 10.2 million accrual reversal related to ATLAS-IT-05.

  • Cash and short-term investments of NOK 100–100.3 million as of June 30, 2025, provide operational runway into 2026.

  • Strengthened board and management to support late-stage execution and commercialization.

Financial highlights

  • Q2 2025 net loss substantially reduced due to a NOK 10.2 million one-off accrual reversal and lower R&D activity.

  • Cash and short-term investments at period end totaled NOK 100–100.3 million.

  • Total liabilities decreased from NOK 38.6 million at year-end 2024 to NOK 20–20.1 million at June 2025.

  • Loss from operations for H1 2025 was NOK 18.6 million, improved from NOK 40.2 million in H1 2024.

  • Equity ratio improved to 81.7% as of June 30, 2025.

Outlook and guidance

  • Interim data from the NeoLIPA melanoma study expected in November 2025; top-line results in H1 2026.

  • Preparations for pivotal Phase III BCC trial ongoing, with milestone payment expected upon study start, likely in H1 2026.

  • LTX-401 preclinical program advancing toward clinical development.

  • Additional genomic and immune response data from Verrica’s Phase II BCC study to be presented later in 2025.

  • Continued focus on cost control and flexibility for key catalysts in H2 2025.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Lytix Biopharma earnings date

Logotype for Lytix Biopharma
Q3 202518 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Lytix Biopharma earnings date

Logotype for Lytix Biopharma
Q3 202518 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Lytix Biopharma is a clinical-stage biotechnology company focused on developing cancer immunotherapies. The company specializes in using oncolytic peptides, which are designed to kill cancer cells and stimulate the immune system to generate a strong, systemic T-cell response. This approach aims to overcome the challenges of tumor heterogeneity, where variations in cancer cells within a tumor reduce the effectiveness of conventional immunotherapies. The company is headquartered in Oslo, Norway, and its shares are listed on the Oslo Stock Exchange.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage